Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
BIIB vs. ILMN: Which Stock Should Value Investors Buy Now?
01:56pm, Monday, 25'th Jul 2022
BIIB vs. ILMN: Which Stock Is the Better Value Option?
Biogen Inc. (BIIB) Upgraded to Buy: What Does It Mean for the Stock?
01:56pm, Monday, 25'th Jul 2022
Biogen Inc. (BIIB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Biogen tops Q2 2022 earnings and revenue estimates
02:18am, Sunday, 24'th Jul 2022
Biogen Inc (NASDAQ: BIIB) has announced a Q2 2002 revenue of $2.589 billion. GAAP net income was $1.058 billion or $7.24 per diluted share, and non-GAAP net income was $767 million or earnings of $5.2
2nd-Quarter Earnings Results Could Impact Drug Company Shares
04:58pm, Friday, 22'nd Jul 2022
The second-quarter earnings season is upon us, and the news coming out of several members of Big Pharma could potentially shake up their share prices. Beyond that, several unknowns could impact top-ti
With All Eyes On Lecanemab Read Out In Alzheimer's, Uncertainty Overshadows Biogen's Q2 Beat
07:44pm, Thursday, 21'st Jul 2022 Benzinga
Yesterday, Biogen Inc (NASDAQ: BIIB) reported Q2 earnings. Needham writes that while operational performance looked good, uncertainty looms over the company's growth potential.
Lecanemab Phase 3
Ionis (IONS) Partner Wraps Up Cardiovascular Study Enrollment
02:40pm, Thursday, 21'st Jul 2022 Zacks Investment Research
Ionis' (IONS) partner, Novartis completes enrolling patients in a phase III study on pelacarsen for treating cardiovascular disease due to elevated Lp(a) levels. Data from this study is expected in 20
Tesla to $1,175? Here Are 5 Other Price Target Changes for Thursday
11:20am, Thursday, 21'st Jul 2022 Benzinga
Mizuho raised Tesla, Inc. (NASDAQ: TSLA) price target from $1,150 to $1,175. However, Mizuho analyst Vijay Rakesh maintained a Buy rating on the stock. Tesla shares rose 3.3% to $766.88 in pre-mark
Why Baker Hughes Shares Dropped 8%; Here Are 64 Biggest Movers From Yesterday
08:40am, Thursday, 21'st Jul 2022 Benzinga
Gainers
Pagaya Technologies Ltd. (NASDAQ: PGY) shares climbed 129.6% to close at $6.20 on Wednesday. Pagaya Technologies is expected to announce its Q2 earnings on August 16, 2022.
Direct Digital Ho
Biogen Reveals $900M Settlement In Whistleblower's MS Drug Kickbacks Lawsuit Days Before Trial
06:15am, Thursday, 21'st Jul 2022 Benzinga
Biogen, Inc. (NASDAQ: BIIB) disclosed in its second-quarter earnings report that it recorded $900 million related to a settlement agreement to resolve previously disclosed "qui tam" litigation rel
Nasdaq leads stocks to finish higher as upbeat tech earnings boost investors confidence
08:21pm, Wednesday, 20'th Jul 2022 MarketWatch
U.S. stock indexes were higher Wednesday, as investors await more corporate earnings, with Tesla due to report after the market closes.
Biogen (BIIB) Q2 2022 Earnings Call Transcript
07:00pm, Wednesday, 20'th Jul 2022 The Motley Fool
BIIB earnings call for the period ending June 30, 2022.
Biogen (BIIB) Beats on Q2 Earnings & Sales, Ups 2022 Guidance
01:14pm, Wednesday, 20'th Jul 2022 Zacks Investment Research
Biogen (BIIB) beats second-quarter estimates for both earnings and sales. Stock falls despite an increase in the 2022 outlook.
Biogen Inc. (BIIB) Q2 Earnings and Revenues Surpass Estimates
12:25pm, Wednesday, 20'th Jul 2022 Zacks Investment Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 28.36% and 4.69%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Bernstein still sees more pain ahead for stocks, until capitulation triggers bonafide rally next year
11:45am, Wednesday, 20'th Jul 2022 MarketWatch
Our call of the day from Bernstein analysts sees things looking up down the road for stocks, but more capitulation in this market will be needed.
Biogen (BIIB) Beats on Q2 Earnings & Sales, Ups 2022 Guidance
10:54am, Wednesday, 20'th Jul 2022
Biogen (BIIB) beats second-quarter estimates for both earnings and sales. Stock falls despite an increase in the 2022 outlook.
